
Alphabiome.ai analyzes the human microbiome with AI to predict treatment outcomes. Its proprietary, reference-free analysis of microbial DNA identifies biomarkers for drug development and clinical decision-making. The platform classifies as a B2B SaaS solution for pharma, biotech, and healthcare providers. Core tech includes AI-driven genomics, biomarker discovery, and integrations with clinical workflows and decision support. The technology aims to scale across large datasets to transform disease understanding and precision medicine.

Alphabiome.ai analyzes the human microbiome with AI to predict treatment outcomes. Its proprietary, reference-free analysis of microbial DNA identifies biomarkers for drug development and clinical decision-making. The platform classifies as a B2B SaaS solution for pharma, biotech, and healthcare providers. Core tech includes AI-driven genomics, biomarker discovery, and integrations with clinical workflows and decision support. The technology aims to scale across large datasets to transform disease understanding and precision medicine.